BioSpace News Archive

Drug Development

Biogen and Eisai Announce Presentation of Detailed Analyses from the Phase 1b Long-Term Extension Study of Aducanumab at CTAD

Three- and four-year data continued to show reduction in amyloid plaque and to suggest a slowing of the rate of clinical decline in patients.

November 9, 2018
·
6 min read
IVI Middle East Clinic to provide Fetal screening and diagnosis for women with low as well as high-risk pregnancies

The center aims to provide streamlined care for women expecting a child

November 9, 2018
·
2 min read
Policy

Gottlieb Outlines Efforts the FDA Is Making to Improve Its Expanded Access Program

Scott Gottlieb, commissioner of the Food and Drug Administration (FDA), provided an update on the agency’s Expanded Access program.

November 9, 2018
·
3 min read
·
Mark Terry
Business

BioSpace Movers and Shakers Nov. 12

Biopharma companies name new members of their leadership teams. Who made big moves this week?

November 9, 2018
·
3 min read
·
Alex Keown
FDA

FDA Action Alert: Theravance’s Approval, Mallinckrodt and Aquestive

The Food and Drug Administration is taking care of a few approvals and committee meetings ahead of the Thanksgiving holiday week. They include drugs for COPD, a pain drug, and a sublingual film formulation of a well-known drug for erectile dysfunction. Here’s a look.

November 9, 2018
·
3 min read
·
Mark Terry
Biotech Bay

Personalis, Inc. Launches ImmunoID NeXT, the First Platform Providing Characterization of a Tumor and Its Microenvironment From a Single Sample

Personalis, a leader in advanced genomics for precision oncology, today announced the launch of its universal cancer immunogenomics platform, ImmunoID NeXT™.

November 9, 2018
·
2 min read
Job Trends

SC18 Exhibitor Profiles

SC18 takes place 12 - 15 November, 2018 at the Kay Bailey Hutchinson Convention Center in Dallas

November 9, 2018
·
11 min read
Drug Development

Arrowhead Pharmaceuticals Presents Late-Breaking Clinical Data on ARO-AAT at Liver Meeting® 2018

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced clinical data from a Phase 1 study of ARO-AAT, the company’s second generation subcutaneously administered RNA interference (RNAi) therapeutic being developed as a treatment for a rare genetic liver disease associated with alpha-1 antitrypsin (AAT) deficiency

November 9, 2018
·
5 min read
Pharm Country

Veterans’ Trust Fund Grant Application Deadline Extended

The Pennsylvania Department of Military and Veterans Affairs (DMVA) has extended the deadline for the 2018-19 Veterans’ Trust Fund (VTF) grant cycle

November 9, 2018
·
2 min read
BioCapital

Success of Hospital Pilot to Document Implants is First Step Leading to Data Analytics Used to Combat Dangers Stated in Netflix Documentary “The Bleeding Edge”

GS1 Ireland led an international coalition which successfully employed a sterile field scanner during surgery.

November 9, 2018
·
10 min read